Sökning: onr:"swepub:oai:DiVA.org:uu-14694" > Effects of fondapar...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03781naa a2200493 4500 | |
001 | oai:DiVA.org:uu-14694 | |
003 | SwePub | |
008 | 080131s2008 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-146942 URI |
024 | 7 | a https://doi.org/10.1093/eurheartj/ehm5782 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Oldgren, Jonas,d 1964-u Uppsala universitet,Institutionen för medicinska vetenskaper,UCR4 aut0 (Swepub:uu)jonaoldg |
245 | 1 0 | a Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment |
264 | c 2008-01-17 | |
264 | 1 | b Oxford University Press (OUP),c 2008 |
338 | a print2 rdacarrier | |
520 | a AIMS: At least one quarter of ST-segment elevation myocardial infarction (STEMI) patients do not receive reperfusion therapy, and these patients are at high risk for new ischaemic events. We evaluated fondaparinux treatment vs. usual care, i.e. placebo or unfractionated (UF) heparin, in a pre-specified subgroup of 2867 (out of 12 092) patients not receiving reperfusion treatment in the OASIS-6 trial. METHODS: In all, 1458 patients were randomized to fondaparinux 2.5 mg once daily subcutaneously up to 8 days and 1409 patients to usual care (control). Randomization was stratified by indication for UF heparin (stratum II, n = 1226) or not (stratum I, n = 1641) based on the investigator's judgment. RESULTS: The proportion of patients who suffered death or myocardial re-infarction at 30 days (primary outcome) was 12.2% in the fondaparinux vs. 15.1% in the control group, hazard ratio (HR) 0.80; 95% confidence interval (CI) 0.65-0.98. There was no increase in severe bleedings, HR 0.82; CI 0.44-1.55, or strokes, HR 0.62; CI 0.29-1.33. Consequently, the composite of death, myocardial re-infarction, or severe bleeding were significantly reduced at 30 days, HR 0.81; CI 0.67-0.99. Reductions in death or myocardial re-infarction at 30 days were consistent in stratum I with fondaparinux vs. placebo, HR 0.88; 95% CI 0.65-1.19, and in stratum II with fondaparinux vs. UF heparin infusion for 24-48 h (n = 806), HR 0.74; CI 95% 0.57-0.97, P = 0.41 for heterogeneity. CONCLUSION: In STEMI patients not receiving reperfusion treatment, fondaparinux reduces the composite of death or myocardial re-infarction without an increase in severe bleedings or strokes as compared to placebo or UF heparin. | |
653 | a Acute myocardial infarction | |
653 | a Anticoagulants | |
653 | a MEDICINE | |
653 | a MEDICIN | |
700 | 1 | a Wallentin, Lars,d 1943-u Uppsala universitet,Institutionen för medicinska vetenskaper,UCR4 aut0 (Swepub:uu)larswall |
700 | 1 | a Afzal, Rizwan4 aut |
700 | 1 | a Bassand, Jean-Pierre4 aut |
700 | 1 | a Budaj, Andrzej4 aut |
700 | 1 | a Chrolavicius, Susan4 aut |
700 | 1 | a Fox, Keith A. A.4 aut |
700 | 1 | a Granger, Christopher B.4 aut |
700 | 1 | a Mehta, Shamir R.4 aut |
700 | 1 | a Pais, Prem4 aut |
700 | 1 | a Peters, Ron J. G.4 aut |
700 | 1 | a Xavier, Denis4 aut |
700 | 1 | a Zhu, Jun4 aut |
700 | 1 | a Yusuf, Salim4 aut |
710 | 2 | a Uppsala universitetb Institutionen för medicinska vetenskaper4 org |
773 | 0 | t European Heart Journald : Oxford University Press (OUP)g 29:3, s. 315-23q 29:3<315-23x 0195-668Xx 1522-9645 |
856 | 4 | u http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=18084015&dopt=Citation |
856 | 4 | u https://academic.oup.com/eurheartj/article-pdf/29/3/315/1365866/ehm578.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-14694 |
856 | 4 8 | u https://doi.org/10.1093/eurheartj/ehm578 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy